Peter Lynch · Growth at a reasonable price (GARP)
Is Halozyme Therapeutics, Inc. (HALO) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
62/100
Does not fit
3/6 criteria passed
Peter Lynch's Criteria, Applied to HALO
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-2.0%
Revenue CAGR ≥ 10%
33.2%
Net margin > 0
23.1%
How HALO Scores on Other Strategies
Live Financial Snapshot
Market cap
$14.89B
P/E (TTM)
23.3x
ROIC (TTM)
23.65%
Gross margin
76.93%
Other Peter Lynch fit reports
Frequently Asked Questions
What is HALO's Peter Lynch fit score?
HALO scores 62/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own HALO?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends HALO.
How often is this score updated?
HALO's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends HALO.
